Stifel analyst Paul Matteis lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $123.00 (from $125.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE